TAFINLAR DABRAFENIB 50 AND 75 mg

DESCRIPTION

Tafinlar is a prescribed medicine. Tafinlar interferes with the growth and spread of cancer cells in the body and is also used to treat certain types of cancer in people who have a ‘BRAF’ gene mutation . It is also used to treat skin cancer (melanoma) , non-small cell lung cancer and thyroid cancer. To buy Tafinlar or to know its price contact 3S Corporation.

Manufacturer :- Novartis Pharmaceuticals Corporation.

ADDITIONAL INFORMATION

Strengths available :- 50 mg and 75 mg

Form :- Capsules

Storage :- Store at 25 ° C

Is the medicine FDA approved :- US FDA Approved

Date of approval :- 29 May , 2013

Dosage :- The recommended dosage regimen of TAFINLAR is 150 mg orally taken twice daily, approximately 12 hours apart as a single agent or with trametinib. Continue treatment until disease progression or unacceptable toxicity occurs.Take TAFINLAR at least 1 hour before or 2 hours after a meal. Do not take a missed dose of TAFINLAR within 6 hours of the next dose of TAFINLAR. Do not open, crush, or break TAFINLAR capsules.

SIDE EFFECTS

Common side effects of Tafinlar include: squamous cell carcinoma, fever, and hyperglycemia. Other side effects include: keratoacanthom

PACK SIZE

Pack of 120 capsules

3S Corporation is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of TAFINLAR DABRAFENIB 50 AND 75 mg based in India - To buy TAFINLAR DABRAFENIB 50 AND 75 mg or know its cost price contact us here.

We supply & sell TAFINLAR DABRAFENIB 50 AND 75 mg for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.

You might also like or love to try

Acalabrutinib 100 mg Capsule

Remdesivir 100 mg Injection

Erleada 60 mg Tablets

Disclaimer: All trademarks, logos and brand names are the property of their respective owners, used here solely for identification & reference only under Section 30(1) of the Trade Marks Act, 1999. We are not affiliated with or endorsed by them unless explicitly stated. By using this website, you agree to these terms.